By Ruchika Sharma

Copyright medicaldialogues

Aurobindo Pharma has announced that Helix Healthcare B.V., a wholly owned subsidiary of the Company, has incorporated a new wholly owned subsidiary in Malaysia by the name of Aurobindo Pharma (Malaysia) SDN. BHD.The object of incorporation of this wholly owned subsidiary is to expand the Pharmaceutical Products business in Malaysia.According to the disclosure on BSE, the Malaysian subsidiary was incorporated on September 17, 2025, with an initial share capital of RM 400,000 (approximately USD 100,000) divided into 400,000 shares of nominal value of RM 1.00 each.No governmental or regulatory approvals were required for this incorporation.Read also: Aurobindo Pharma’s subsidiary CuraTeQ Biologics Secures MHRA Approval for Trastuzumab Biosimilar Dazublys in HER2-Positive CancerHeadquartered in Hyderabad, India, Aurobindo Pharma Ltd. is a leading global pharmaceutical company with operations spanning active pharmaceutical ingredients (APIs), generics, and biosimilars. CuraTeQ Biologics is its wholly owned subsidiary focused on biosimilars for oncology and other therapeutic areas, enhancing Aurobindo’s footprint in biologics markets in Europe and beyond.